Maravai LifeSciences (MRVI) Financials

$2.22 -0.08 (-3.48%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$2.22 +0.00 (+0.23%)

As of 05/23/2025 04:04 PM Eastern

Annual Income Statements for Maravai LifeSciences

This table shows Maravai LifeSciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-145	-119	220
Consolidated Net Income / (Loss)	-260	-138	491
Net Income / (Loss) Continuing Operations	-260	-138	491
Total Pre-Tax Income	-261	618	551
Total Operating Income	-236	-32	574
Total Gross Profit	108	140	714
Total Revenue	259	289	883
Operating Revenue	259	289	883
Total Cost of Revenue	151	149	169
Operating Cost of Revenue	151	149	169
Total Operating Expenses	344	172	140
Selling, General & Admin Expense	162	151	129
Research & Development Expense	19	17	18
Impairment Charge	166	0.00	0.00
Restructuring Charge	-1.21	6.47	0.00
Other Special Charges / (Income)	-2.00	-3.29	-7.80
Total Other Income / (Expense), net	-26	649	-19
Interest Expense	51	46	21
Interest & Investment Income	27	28	2.34
Other Income / (Expense), net	-2.34	668	-0.36
Income Tax Expense	-1.86	756	61
Net Income / (Loss) Attributable to Noncontrolling Interest	-115	-19	270
Basic Earnings per Share	($1.05)	($0.90)	$1.67
Weighted Average Basic Shares Outstanding	137.91M	131.92M	131.55M
Diluted Earnings per Share	($1.05)	($0.90)	$1.67
Weighted Average Diluted Shares Outstanding	137.91M	131.92M	255.32M
Weighted Average Basic & Diluted Shares Outstanding	254.34M	251.40M	250.88M

This table shows Maravai LifeSciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-26	-99	-7.59	-12	-106	-6.46	-6.54	-0.07	38	44
Consolidated Net Income / (Loss)	-46	-176	-14	-23	-110	-15	-12	-1.35	87	100
Net Income / (Loss) Continuing Operations	-46	-176	-14	-23	-110	-15	-12	-1.35	87	100
Total Pre-Tax Income	-47	-176	-17	-22	656	-21	-13	-4.52	96	114
Total Operating Income	-38	-169	-9.51	-19	-7.15	-15	-12	2.53	109	117
Total Gross Profit	19	28	35	26	39	30	26	45	151	153
Total Revenue	56	65	73	64	74	67	69	79	205	191
Operating Revenue	56	65	73	64	74	67	69	79	205	191
Total Cost of Revenue	37	37	38	38	35	37	43	34	53	38
Operating Cost of Revenue	37	37	38	38	35	37	43	34	53	38
Total Operating Expenses	57	197	45	45	46	46	37	43	42	36
Selling, General & Admin Expense	41	39	41	41	38	39	35	39	37	31
Research & Development Expense	4.56	4.34	5.28	5.03	4.59	4.35	4.19	4.15	5.01	5.39
Restructuring Charge	0.01	-0.00	-0.00	-1.21	6.47	0.00	0.00	0.00	-	-
Total Other Income / (Expense), net	-8.37	-6.49	-7.42	-3.55	663	-5.15	-1.75	-7.06	-9.27	-3.14
Interest Expense	14	14	12	11	15	12	7.02	12	10	3.14
Interest & Investment Income	6.04	7.07	7.09	7.21	7.46	7.43	6.79	6.05	2.34	0.00
Other Income / (Expense), net	0.04	0.07	-2.56	0.11	671	-0.94	-1.52	-1.27	-1.43	-0.00
Income Tax Expense	-0.01	0.31	-2.44	0.27	766	-5.46	-1.42	-3.18	8.45	14
Net Income / (Loss) Attributable to Noncontrolling Interest	-20	-77	-6.91	-11	-4.02	-8.64	-5.40	-1.28	50	55
Basic Earnings per Share	($0.21)	($0.70)	($0.05)	($0.09)	($0.80)	($0.05)	($0.05)	$0.00	$0.28	$0.34
Weighted Average Basic Shares Outstanding	137.91M	141.56M	135.84M	132.33M	131.92M	131.93M	131.86M	131.74M	131.55M	131.54M
Diluted Earnings per Share	($0.21)	($0.70)	($0.05)	($0.09)	($0.80)	($0.05)	($0.05)	$0.00	$0.30	$0.34
Weighted Average Diluted Shares Outstanding	137.91M	141.56M	135.84M	132.33M	131.92M	131.93M	131.86M	131.74M	255.32M	131.65M
Weighted Average Basic & Diluted Shares Outstanding	254.34M	252.53M	252.24M	251.92M	251.40M	251.28M	251.02M	250.98M	250.88M	255.21M

This table details how cash moves in and out of Maravai LifeSciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-253	-57	81
Net Cash From Operating Activities	7.47	126	536
Net Cash From Continuing Operating Activities	7.47	126	536
Net Income / (Loss) Continuing Operations	-260	-138	491
Consolidated Net Income / (Loss)	-260	-138	491
Depreciation Expense	21	13	7.57
Amortization Expense	39	39	33
Non-Cash Adjustments To Reconcile Net Income	222	-637	11
Changes in Operating Assets and Liabilities, net	-15	850	-6.46
Net Cash From Investing Activities	-24	-122	-268
Net Cash From Continuing Investing Activities	-24	-122	-268
Purchase of Property, Plant & Equipment	-30	-66	-17
Acquisitions	-1.80	-70	-239
Divestitures	0.00	0.00	0.62
Other Investing Activities, net	7.14	13	-12
Net Cash From Financing Activities	-236	-61	-187
Net Cash From Continuing Financing Activities	-236	-61	-187
Repayment of Debt	-236	-5.44	-14
Payment of Dividends	-0.49	-9.61	-150
Issuance of Debt	0.95	0.00	8.46
Issuance of Common Equity	-2.08	-0.02	2.36
Other Financing Activities, net	1.55	-46	-34
Cash Interest Paid	51	44	20
Cash Income Taxes Paid	0.67	-2.99	23

This table details how cash moves in and out of Maravai LifeSciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-256	4.99	11	-13	-4.64	-0.57	-48	-3.87	15	67
Net Cash From Operating Activities	-15	13	17	-8.47	7.79	14	19	85	99	110
Net Cash From Continuing Operating Activities	-15	13	17	-8.47	7.79	14	19	85	99	110
Net Income / (Loss) Continuing Operations	-46	-176	-14	-23	-110	-15	-12	-1.35	87	100
Consolidated Net Income / (Loss)	-46	-176	-14	-23	-110	-15	-12	-1.35	87	100
Depreciation Expense	5.47	5.04	5.56	4.79	3.93	4.07	2.82	2.08	1.96	1.86
Amortization Expense	9.72	9.75	9.74	9.71	9.79	9.76	9.71	9.55	8.72	8.78
Non-Cash Adjustments To Reconcile Net Income	27	169	14	12	-660	10	6.01	7.10	5.87	0.49
Changes in Operating Assets and Liabilities, net	-11	5.66	2.97	-13	764	5.43	13	68	-4.65	-0.72
Net Cash From Investing Activities	-4.93	-8.96	-6.18	-4.24	-13	-16	-24	-70	-19	-5.85
Net Cash From Continuing Investing Activities	-4.93	-8.96	-6.18	-4.24	-13	-16	-24	-70	-19	-5.85
Purchase of Property, Plant & Equipment	-5.85	-8.59	-9.55	-5.67	-17	-16	-25	-7.87	-6.21	-6.47
Acquisitions	-0.80	-1.00	-	0.00	-	-	0.11	-70	-0.13	-
Other Investing Activities, net	1.72	0.63	3.37	1.42	3.90	0.31	0.79	7.87	-12	-
Net Cash From Financing Activities	-236	0.81	0.23	-0.56	0.47	0.78	-43	-19	-66	-37
Net Cash From Continuing Financing Activities	-236	0.81	0.23	-0.56	0.47	0.78	-43	-19	-66	-37
Repayment of Debt	-232	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36	-1.36
Payment of Dividends	0.08	-	-0.57	0.00	-	-	-1.31	-8.30	-31	-37
Issuance of Common Equity	-0.60	-0.02	-0.03	-1.43	-0.35	0.31	0.35	-0.33	0.37	0.73
Other Financing Activities, net	-5.06	2.19	2.19	2.23	2.18	1.83	-41	-9.21	-34	-
Cash Interest Paid	15	12	12	12	12	12	11	9.59	8.78	5.28
Cash Income Taxes Paid	0.03	0.27	0.18	0.20	0.09	-3.01	0.45	-0.52	3.45	5.73

This table presents Maravai LifeSciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,008	1,487	2,282
Total Current Assets	429	700	848
Cash & Equivalents	322	575	632
Accounts Receivable	39	55	139
Inventories, net	50	51	43
Prepaid Expenses	18	19	26
Plant, Property, & Equipment, net	164	0.00	0.00
Total Noncurrent Assets	415	788	1,434
Goodwill	160	326	284
Intangible Assets	195	221	217
Other Noncurrent Operating Assets	60	241	168
Total Liabilities & Shareholders' Equity	1,008	1,487	2,282
Total Liabilities	431	698	1,377
Total Current Liabilities	57	87	110
Short-Term Debt	5.44	5.44	5.44
Accounts Payable	12	18	48
Accrued Expenses	36	60	53
Current Deferred Revenue	2.38	3.36	3.09
Other Current Liabilities	0.79	0.63	0.00
Total Noncurrent Liabilities	374	610	1,267
Long-Term Debt	290	519	522
Other Noncurrent Operating Liabilities	84	91	745
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	577	790	905
Total Preferred & Common Equity	325	417	545
Total Common Equity	325	417	545
Common Stock	184	131	140
Retained Earnings	141	286	405
Noncontrolling Interest	252	373	360

This table presents Maravai LifeSciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,278	1,448	1,445	2,268	2,264	2,315	2,249
Total Current Assets	679	685	668	701	699	766	836
Cash & Equivalents	578	573	562	580	580	628	617
Accounts Receivable	29	39	37	46	49	56	114
Inventories, net	50	49	50	49	47	55	62
Prepaid Expenses	22	17	17	23	23	26	23
Plant, Property, & Equipment, net	0.00	0.00	162	0.00	0.00	88	48
Total Noncurrent Assets	599	762	615	1,567	1,565	1,462	1,365
Goodwill	172	326	326	326	326	327	284
Intangible Assets	202	207	214	228	235	242	223
Other Noncurrent Operating Assets	225	229	75	239	234	127	87
Total Liabilities & Shareholders' Equity	1,278	1,448	1,445	2,268	2,264	2,315	2,249
Total Liabilities	665	671	667	1,375	1,367	1,415	1,407
Total Current Liabilities	63	69	59	78	75	125	116
Short-Term Debt	5.44	5.44	5.44	5.44	5.44	5.74	5.44
Accounts Payable	17	20	15	14	16	47	44
Accrued Expenses	38	41	35	56	50	70	60
Current Deferred Revenue	1.83	2.08	2.21	2.55	2.46	2.05	5.82
Other Current Liabilities	0.75	0.71	0.67	0.60	0.56	-	-
Total Noncurrent Liabilities	602	603	608	1,297	1,292	1,290	1,292
Long-Term Debt	516	517	518	520	520	521	523
Other Noncurrent Operating Liabilities	86	86	90	771	763	66	58
Commitments & Contingencies	0.00	0.00	0.00	-	-	-	-
Total Equity & Noncontrolling Interests	613	776	777	892	898	901	842
Total Preferred & Common Equity	345	437	411	519	521	522	504
Total Common Equity	345	437	411	519	521	522	504
Common Stock	178	171	137	128	122	117	137
Retained Earnings	167	266	274	392	398	405	367
Noncontrolling Interest	268	339	367	373	377	379	338

This table displays calculated financial ratios and metrics derived from Maravai LifeSciences' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	-10.30%	-67.28%	10.48%
EBITDA Growth	-125.92%	11.85%	2.93%
EBIT Growth	-137.42%	10.81%	2.29%
NOPAT Growth	-2,426.50%	-98.61%	4.19%
Net Income Growth	-87.62%	-128.20%	4.56%
EPS Growth	-16.67%	-153.89%	7.05%
Operating Cash Flow Growth	-94.09%	-76.45%	45.42%
Free Cash Flow Firm Growth	-65.88%	-92.77%	527.78%
Invested Capital Growth	-25.48%	-7.68%	-35.34%
Revenue Q/Q Growth	-6.40%	-31.12%	-2.62%
EBITDA Q/Q Growth	-134.10%	453.80%	-6.53%
EBIT Q/Q Growth	-151.26%	742.34%	-7.11%
NOPAT Q/Q Growth	-210.06%	-91.86%	-6.66%
Net Income Q/Q Growth	19.65%	-334.39%	-7.48%
EPS Q/Q Growth	35.98%	-550.00%	-7.73%
Operating Cash Flow Q/Q Growth	-75.03%	-42.04%	8.19%
Free Cash Flow Firm Q/Q Growth	-94.57%	-90.39%	195.96%
Invested Capital Q/Q Growth	-1.07%	-11.77%	-45.31%
Profitability Metrics	-	-	-
Gross Margin	41.79%	48.52%	80.87%
EBITDA Margin	-68.75%	237.97%	69.62%
Operating Margin	-90.91%	-10.95%	65.03%
EBIT Margin	-91.81%	220.08%	64.99%
Profit (Net Income) Margin	-100.17%	-47.89%	55.57%
Tax Burden Percent	99.29%	-22.40%	88.97%
Interest Burden Percent	109.89%	97.14%	96.10%
Effective Tax Rate	0.00%	122.40%	11.03%
Return on Invested Capital (ROIC)	-25.57%	0.92%	50.12%
ROIC Less NNEP Spread (ROIC-NNEP)	219.48%	187.99%	43.24%
Return on Net Nonoperating Assets (RNNOA)	-12.41%	-17.25%	17.53%
Return on Equity (ROE)	-37.98%	-16.33%	67.65%
Cash Return on Invested Capital (CROIC)	3.63%	8.91%	93.05%
Operating Return on Assets (OROA)	-19.07%	33.74%	27.32%
Return on Assets (ROA)	-20.81%	-7.34%	23.36%
Return on Common Equity (ROCE)	-20.62%	-9.27%	40.14%
Return on Equity Simple (ROE_SIMPLE)	-79.81%	-33.20%	89.99%
Net Operating Profit after Tax (NOPAT)	-165	7.09	511
NOPAT Margin	-63.63%	2.45%	57.86%
Net Nonoperating Expense Percent (NNEP)	-245.05%	-187.07%	6.88%
Return On Investment Capital (ROIC_SIMPLE)	-18.89%	0.54%	35.66%
Cost of Revenue to Revenue	58.21%	51.48%	19.13%
SG&A Expenses to Revenue	62.42%	52.39%	14.64%
R&D to Revenue	7.42%	5.98%	2.08%
Operating Expenses to Revenue	132.70%	59.48%	15.84%
Earnings before Interest and Taxes (EBIT)	-238	636	574
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-178	688	615
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.23	3.95	6.70
Price to Tangible Book Value (P/TBV)	0.00	0.00	81.36
Price to Revenue (P/Rev)	5.31	5.70	4.14
Price to Earnings (P/E)	0.00	0.00	16.58
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	6.03%
Enterprise Value to Invested Capital (EV/IC)	2.91	2.66	4.88
Enterprise Value to Revenue (EV/Rev)	6.18	6.81	4.43
Enterprise Value to EBITDA (EV/EBITDA)	0.00	2.86	6.36
Enterprise Value to EBIT (EV/EBIT)	0.00	3.10	6.81
Enterprise Value to NOPAT (EV/NOPAT)	0.00	277.63	7.65
Enterprise Value to Operating Cash Flow (EV/OCF)	214.56	15.59	7.29
Enterprise Value to Free Cash Flow (EV/FCFF)	68.46	28.71	4.12
Leverage & Solvency	-	-	-
Debt to Equity	0.51	0.66	0.58
Long-Term Debt to Equity	0.50	0.66	0.58
Financial Leverage	-0.06	-0.09	0.41
Leverage Ratio	1.83	2.22	2.90
Compound Leverage Factor	2.01	2.16	2.78
Debt to Total Capital	33.89%	39.89%	36.81%
Short-Term Debt to Total Capital	0.62%	0.41%	0.38%
Long-Term Debt to Total Capital	33.27%	39.47%	36.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	28.85%	28.40%	25.13%
Common Equity to Total Capital	37.26%	31.72%	38.06%
Debt to EBITDA	-1.66	0.76	0.86
Net Debt to EBITDA	0.15	-0.07	-0.17
Long-Term Debt to EBITDA	-1.63	0.75	0.85
Debt to NOPAT	-1.79	73.94	1.03
Net Debt to NOPAT	0.16	-7.17	-0.20
Long-Term Debt to NOPAT	-1.76	73.17	1.02
Altman Z-Score	2.03	3.78	3.44
Noncontrolling Interest Sharing Ratio	45.72%	43.25%	40.66%
Liquidity Ratios	-	-	-
Current Ratio	7.53	8.00	7.70
Quick Ratio	6.34	7.20	7.00
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	23	69	949
Operating Cash Flow to CapEx	25.17%	192.55%	3,136.20%
Free Cash Flow to Firm to Interest Expense	0.46	1.49	46.00
Operating Cash Flow to Interest Expense	0.15	2.75	25.99
Operating Cash Flow Less CapEx to Interest Expense	-0.44	1.32	25.16
Efficiency Ratios	-	-	-
Asset Turnover	0.21	0.15	0.42
Accounts Receivable Turnover	5.57	2.99	6.89
Inventory Turnover	2.97	3.15	3.57
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	10.14	4.50	3.70
Days Sales Outstanding (DSO)	65.57	122.05	52.94
Days Inventory Outstanding (DIO)	122.75	116.01	102.30
Days Payable Outstanding (DPO)	35.99	81.03	98.55
Cash Conversion Cycle (CCC)	152.33	157.02	56.69
Capital & Investment Metrics	-	-	-
Invested Capital	551	739	801
Invested Capital Turnover	0.40	0.38	0.87
Increase / (Decrease) in Invested Capital	-188	-61	-438
Enterprise Value (EV)	1,602	1,968	3,907
Market Capitalization	1,376	1,646	3,652
Book Value per Share	$1.29	$1.66	$2.14
Tangible Book Value per Share	($0.12)	($0.52)	$0.18
Total Capital	873	1,314	1,433
Total Debt	296	524	527
Total Long-Term Debt	290	519	522
Net Debt	-26	-51	-105
Capital Expenditures (CapEx)	30	66	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	55	43	111
Debt-free Net Working Capital (DFNWC)	378	618	743
Net Working Capital (NWC)	372	612	738
Net Nonoperating Expense (NNE)	95	145	20
Net Nonoperating Obligations (NNO)	-26	-51	-105
Total Depreciation and Amortization (D&A)	60	52	41
Debt-free, Cash-free Net Working Capital to Revenue	21.30%	14.85%	12.58%
Debt-free Net Working Capital to Revenue	145.69%	213.84%	84.17%
Net Working Capital to Revenue	143.59%	211.96%	83.55%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.05)	($0.90)	$1.67
Adjusted Weighted Average Basic Shares Outstanding	137.91M	131.92M	131.55M
Adjusted Diluted Earnings per Share	($1.05)	($0.90)	$1.67
Adjusted Weighted Average Diluted Shares Outstanding	137.91M	131.92M	255.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	254.34M	251.40M	250.88M
Normalized Net Operating Profit after Tax (NOPAT)	-51	-20	504
Normalized NOPAT Margin	-19.63%	-6.90%	57.07%
Pre Tax Income Margin	-100.89%	213.79%	62.45%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-4.68	13.86	27.83
NOPAT to Interest Expense	-3.24	0.15	24.77
EBIT Less CapEx to Interest Expense	-5.26	12.43	27.00
NOPAT Less CapEx to Interest Expense	-3.82	-1.27	23.95
Payout Ratios	-	-	-
Dividend Payout Ratio	-0.19%	-6.94%	30.61%
Augmented Payout Ratio	-0.19%	-6.94%	30.61%

This table displays calculated financial ratios and metrics derived from Maravai LifeSciences' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-23.92%	-2.49%	6.51%	-18.79%	-63.78%	-65.04%	-71.61%	-67.65%	-10.39%	-6.61%
EBITDA Growth	-103.38%	-6,011.29%	630.86%	-133.06%	472.01%	-101.98%	-100.32%	-92.83%	-26.61%	-25.37%
EBIT Growth	-105.73%	-933.39%	8.06%	-1,582.61%	515.96%	-113.99%	-107.32%	-99.25%	-28.93%	-26.34%
NOPAT Growth	-2,327.23%	-996.93%	18.10%	-844.61%	-98.80%	-110.54%	-105.02%	-98.80%	-26.62%	-24.70%
Net Income Growth	57.72%	-1,065.11%	-21.34%	-1,582.49%	-225.80%	-115.15%	-107.62%	-100.92%	-31.22%	-24.61%
EPS Growth	73.75%	-1,300.00%	0.00%	0.00%	-366.67%	-114.71%	-109.43%	-100.00%	-31.82%	-22.73%
Operating Cash Flow Growth	-287.91%	-7.27%	-9.17%	-109.95%	-92.16%	-87.13%	-88.32%	-47.58%	69.10%	4.26%
Free Cash Flow Firm Growth	157.91%	-73.58%	-81.90%	2,799.44%	-88.33%	594.47%	275.66%	92.83%	363.99%	88.70%
Invested Capital Growth	-25.48%	-33.54%	-13.93%	-50.51%	-7.68%	-42.77%	-42.38%	2.00%	-35.34%	18.34%
Revenue Q/Q Growth	-13.49%	-11.17%	14.37%	-13.44%	10.88%	-2.97%	-12.79%	-61.40%	7.03%	-21.20%
EBITDA Q/Q Growth	85.15%	-4,894.81%	175.48%	-100.63%	26,956.18%	-316.50%	-104.70%	-88.73%	-7.08%	-32.54%
EBIT Q/Q Growth	77.47%	-1,300.05%	35.62%	-102.82%	4,159.95%	-24.56%	-1,138.18%	-98.78%	-7.77%	-34.85%
NOPAT Q/Q Growth	77.45%	-1,677.90%	49.57%	-1,201.70%	111.10%	-32.75%	-558.51%	-98.22%	-2.72%	-36.72%
Net Income Q/Q Growth	73.58%	-1,114.15%	36.10%	79.38%	-628.26%	-26.45%	-785.98%	-101.54%	-12.27%	-36.41%
EPS Q/Q Growth	70.00%	-1,300.00%	44.44%	88.75%	-1,500.00%	0.00%	0.00%	-100.00%	-11.76%	-35.85%
Operating Cash Flow Q/Q Growth	-211.43%	-24.65%	305.91%	-208.69%	-45.01%	-26.20%	-77.44%	-14.36%	-9.74%	-33.00%
Free Cash Flow Firm Q/Q Growth	-0.57%	46.70%	-85.05%	1,082.35%	-89.81%	0.53%	2,329.79%	-105.11%	531.74%	64.29%
Invested Capital Q/Q Growth	-1.07%	-23.30%	-1.79%	-0.01%	-11.77%	-0.66%	-43.53%	86.53%	-45.31%	0.02%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	33.62%	43.52%	47.86%	40.27%	52.65%	45.13%	37.21%	57.39%	73.99%	80.04%
EBITDA Margin	-40.60%	-236.58%	4.38%	-6.64%	914.27%	-3.77%	-0.88%	16.31%	57.89%	66.68%
Operating Margin	-67.60%	-259.38%	-12.96%	-29.39%	-9.64%	-23.06%	-16.85%	3.21%	53.37%	61.12%
EBIT Margin	-67.52%	-259.27%	-16.45%	-29.22%	895.76%	-24.46%	-19.06%	1.60%	52.67%	61.12%
Profit (Net Income) Margin	-82.43%	-269.87%	-19.74%	-35.34%	-148.34%	-22.59%	-17.33%	-1.71%	42.71%	52.10%
Tax Burden Percent	99.98%	100.18%	85.61%	101.21%	-16.76%	73.44%	89.37%	29.80%	91.19%	87.60%
Interest Burden Percent	122.09%	103.91%	140.19%	119.48%	98.80%	125.71%	101.76%	-357.55%	88.92%	97.32%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	116.76%	0.00%	0.00%	0.00%	8.81%	12.40%
Return on Invested Capital (ROIC)	-19.02%	-72.12%	-3.22%	-5.05%	0.61%	-5.88%	-5.56%	1.09%	42.15%	35.95%
ROIC Less NNEP Spread (ROIC-NNEP)	32.23%	31.55%	11.69%	-8.47%	143.59%	-7.40%	-6.76%	0.64%	38.01%	35.56%
Return on Net Nonoperating Assets (RNNOA)	-1.82%	-2.33%	-0.73%	-2.80%	-13.17%	-2.42%	-2.57%	0.58%	15.41%	38.58%
Return on Equity (ROE)	-20.84%	-74.45%	-3.96%	-7.85%	-12.57%	-8.31%	-8.13%	1.67%	57.56%	74.54%
Cash Return on Invested Capital (CROIC)	3.63%	61.79%	16.74%	68.84%	8.91%	61.98%	70.83%	22.97%	93.05%	23.73%
Operating Return on Assets (OROA)	-14.02%	-40.50%	-2.47%	-4.26%	137.32%	-4.54%	-4.67%	0.53%	22.14%	26.75%
Return on Assets (ROA)	-17.12%	-42.15%	-2.96%	-5.15%	-22.74%	-4.20%	-4.25%	-0.56%	17.96%	22.80%
Return on Common Equity (ROCE)	-11.31%	-42.75%	-2.26%	-4.36%	-7.13%	-4.90%	-4.76%	0.97%	34.16%	46.40%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-93.62%	-37.14%	-38.89%	0.00%	11.37%	33.38%	65.67%	0.00%	105.28%
Net Operating Profit after Tax (NOPAT)	-27	-118	-6.66	-13	1.20	-11	-8.13	1.77	100	102
NOPAT Margin	-47.32%	-181.56%	-9.07%	-20.57%	1.62%	-16.14%	-11.80%	2.24%	48.66%	53.54%
Net Nonoperating Expense Percent (NNEP)	-51.25%	-103.67%	-14.91%	3.42%	-142.98%	1.52%	1.20%	0.45%	4.15%	0.39%
Return On Investment Capital (ROIC_SIMPLE)	-3.06%	-	-	-	0.09%	-	-	-	6.95%	-
Cost of Revenue to Revenue	66.38%	56.48%	52.14%	59.73%	47.35%	54.87%	62.79%	42.61%	26.01%	19.96%
SG&A Expenses to Revenue	73.12%	59.95%	55.25%	63.70%	51.90%	58.12%	51.34%	48.94%	18.17%	16.10%
R&D to Revenue	8.09%	6.66%	7.20%	7.84%	6.20%	6.50%	6.09%	5.25%	2.45%	2.82%
Operating Expenses to Revenue	101.22%	302.90%	60.82%	69.66%	62.29%	68.19%	54.06%	54.18%	20.62%	18.92%
Earnings before Interest and Taxes (EBIT)	-38	-169	-12	-19	664	-16	-13	1.27	108	117
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-23	-154	3.22	-4.26	678	-2.52	-0.61	13	119	128
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.23	6.07	4.13	5.31	3.95	4.83	5.99	6.74	6.70	12.93
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	81.36	0.00
Price to Revenue (P/Rev)	5.31	7.57	6.47	7.95	5.70	5.98	5.74	4.90	4.14	7.19
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	102.19	41.32	22.93	16.58	27.33
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.98%	2.42%	4.36%	6.03%	3.66%
Enterprise Value to Invested Capital (EV/IC)	2.91	4.15	2.88	3.39	2.66	3.38	4.08	2.55	4.88	4.62
Enterprise Value to Revenue (EV/Rev)	6.18	8.33	7.51	9.15	6.81	6.74	6.33	5.31	4.43	7.46
Enterprise Value to EBITDA (EV/EBITDA)	0.00	4.42	3.10	3.74	2.86	22.78	13.54	8.58	6.36	10.28
Enterprise Value to EBIT (EV/EBIT)	0.00	4.97	3.39	4.07	3.10	37.47	16.49	9.49	6.81	10.95
Enterprise Value to NOPAT (EV/NOPAT)	0.00	15.40	150.97	177.59	277.63	32.47	17.50	10.33	7.65	12.36
Enterprise Value to Operating Cash Flow (EV/OCF)	214.56	77.20	67.67	76.74	15.59	12.99	10.97	8.30	7.29	13.65
Enterprise Value to Free Cash Flow (EV/FCFF)	68.46	5.36	15.93	3.26	28.71	3.97	4.21	11.22	4.12	21.11
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.51	0.85	0.67	0.67	0.66	0.59	0.59	0.60	0.58	0.63
Long-Term Debt to Equity	0.50	0.84	0.67	0.67	0.66	0.58	0.58	0.60	0.58	0.62
Financial Leverage	-0.06	-0.07	-0.06	0.33	-0.09	0.33	0.38	0.90	0.41	1.08
Leverage Ratio	1.83	2.36	2.22	2.24	2.22	2.60	2.65	2.80	2.90	3.20
Compound Leverage Factor	2.23	2.45	3.11	2.68	2.20	3.27	2.70	-10.02	2.58	3.11
Debt to Total Capital	33.89%	45.97%	40.23%	40.23%	39.89%	37.04%	36.94%	37.63%	36.81%	38.56%
Short-Term Debt to Total Capital	0.62%	0.48%	0.42%	0.42%	0.41%	0.38%	0.38%	0.40%	0.38%	0.40%
Long-Term Debt to Total Capital	33.27%	45.49%	39.81%	39.82%	39.47%	36.66%	36.56%	37.24%	36.44%	38.16%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	28.85%	23.61%	26.14%	28.19%	28.40%	26.32%	26.49%	26.25%	25.13%	24.67%
Common Equity to Total Capital	37.26%	30.41%	33.64%	31.57%	31.72%	36.64%	36.57%	36.11%	38.06%	36.77%
Debt to EBITDA	-1.66	1.00	0.77	0.78	0.76	4.23	2.07	1.22	0.86	0.80
Net Debt to EBITDA	0.15	-0.11	-0.08	-0.06	-0.07	-0.44	-0.21	-0.19	-0.17	-0.14
Long-Term Debt to EBITDA	-1.63	0.99	0.77	0.77	0.75	4.18	2.05	1.21	0.85	0.79
Debt to NOPAT	-1.79	3.48	37.70	37.06	73.94	6.03	2.67	1.47	1.03	0.97
Net Debt to NOPAT	0.16	-0.38	-3.65	-2.72	-7.17	-0.63	-0.28	-0.23	-0.20	-0.16
Long-Term Debt to NOPAT	-1.76	3.45	37.30	36.67	73.17	5.96	2.64	1.46	1.02	0.96
Altman Z-Score	2.69	2.43	2.55	2.88	3.85	1.83	2.17	2.38	2.77	3.97
Noncontrolling Interest Sharing Ratio	45.72%	42.58%	42.80%	44.45%	43.25%	41.00%	41.54%	41.86%	40.66%	37.74%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.53	10.74	10.00	11.32	8.00	8.96	9.33	6.13	7.70	7.22
Quick Ratio	6.34	9.60	8.92	10.14	7.20	7.99	8.40	5.48	7.00	6.33
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	162	163	111	741	63	615	612	-27	537	-124
Operating Cash Flow to CapEx	-250.27%	152.90%	182.50%	-149.46%	46.37%	89.51%	76.60%	1,081.27%	1,598.57%	1,701.86%
Free Cash Flow to Firm to Interest Expense	11.19	11.92	9.28	68.21	4.07	52.87	87.17	-2.32	52.77	-39.68
Operating Cash Flow to Interest Expense	-1.01	0.96	1.46	-0.78	0.51	1.22	2.73	7.19	9.76	35.10
Operating Cash Flow Less CapEx to Interest Expense	-1.42	0.33	0.66	-1.30	-0.59	-0.14	-0.84	6.52	9.15	33.03
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.21	0.16	0.15	0.15	0.15	0.19	0.25	0.33	0.42	0.44
Accounts Receivable Turnover	5.57	7.43	6.36	5.90	2.99	5.25	6.42	8.13	6.89	10.07
Inventory Turnover	2.97	2.98	3.07	2.93	3.15	2.99	3.13	3.06	3.57	2.61
Fixed Asset Turnover	0.00	0.00	0.00	2.20	0.00	0.00	0.00	10.60	0.00	11.57
Accounts Payable Turnover	10.14	9.79	8.31	4.92	4.50	5.77	4.54	3.53	3.70	5.69
Days Sales Outstanding (DSO)	65.57	49.13	57.41	61.89	122.05	69.49	56.82	44.91	52.94	36.23
Days Inventory Outstanding (DIO)	122.75	122.31	118.92	124.52	116.01	122.00	116.53	119.23	102.30	139.87
Days Payable Outstanding (DPO)	35.99	37.28	43.93	74.16	81.03	63.24	80.35	103.45	98.55	64.14
Cash Conversion Cycle (CCC)	152.33	134.16	132.40	112.25	157.02	128.26	93.00	60.69	56.69	111.96
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	551	557	726	739	739	838	843	1,493	801	1,464
Invested Capital Turnover	0.40	0.40	0.36	0.25	0.38	0.36	0.47	0.49	0.87	0.67
Increase / (Decrease) in Invested Capital	-188	-281	-117	-754	-61	-626	-620	29	-438	227
Enterprise Value (EV)	1,602	2,308	2,093	2,508	1,968	2,829	3,442	3,809	3,907	6,764
Market Capitalization	1,376	2,096	1,804	2,180	1,646	2,510	3,120	3,515	3,652	6,515
Book Value per Share	$1.29	$1.37	$1.73	$1.63	$1.66	$2.07	$2.07	$2.08	$2.14	$1.97
Tangible Book Value per Share	($0.12)	($0.11)	($0.38)	($0.52)	($0.52)	($0.14)	($0.16)	($0.19)	$0.18	($0.01)
Total Capital	873	1,135	1,299	1,301	1,314	1,417	1,423	1,444	1,433	1,370
Total Debt	296	522	523	523	524	525	526	543	527	528
Total Long-Term Debt	290	516	517	518	519	520	520	538	522	523
Net Debt	-26	-56	-51	-38	-51	-55	-54	-85	-105	-89
Capital Expenditures (CapEx)	5.85	8.59	9.55	5.67	17	16	25	7.87	6.21	6.47
Debt-free, Cash-free Net Working Capital (DFCFNWC)	55	43	49	53	43	48	50	18	111	108
Debt-free Net Working Capital (DFNWC)	378	621	622	614	618	628	630	646	743	725
Net Working Capital (NWC)	372	616	617	609	612	623	624	641	738	720
Net Nonoperating Expense (NNE)	20	58	7.83	9.48	111	4.31	3.81	3.12	12	2.75
Net Nonoperating Obligations (NNO)	-26	-56	-51	-38	-51	-55	-54	593	-105	622
Total Depreciation and Amortization (D&A)	15	15	15	14	14	14	13	12	11	11
Debt-free, Cash-free Net Working Capital to Revenue	21.30%	15.58%	17.62%	19.19%	14.85%	11.55%	9.13%	2.52%	12.58%	11.90%
Debt-free Net Working Capital to Revenue	145.69%	224.36%	223.36%	224.12%	213.84%	149.71%	115.80%	90.06%	84.17%	79.99%
Net Working Capital to Revenue	143.59%	222.40%	221.41%	222.13%	211.96%	148.41%	114.80%	89.26%	83.55%	79.39%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.21)	($0.70)	($0.05)	($0.09)	($0.80)	($0.05)	($0.05)	$0.00	$0.28	$0.34
Adjusted Weighted Average Basic Shares Outstanding	137.91M	141.56M	135.84M	132.33M	131.92M	131.93M	131.86M	131.74M	131.55M	131.54M
Adjusted Diluted Earnings per Share	($0.21)	($0.70)	($0.05)	($0.09)	($0.80)	($0.05)	($0.05)	$0.00	$0.30	$0.34
Adjusted Weighted Average Diluted Shares Outstanding	137.91M	141.56M	135.84M	132.33M	131.92M	131.93M	131.86M	131.74M	255.32M	131.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	254.34M	252.53M	252.24M	251.92M	251.40M	251.28M	251.02M	250.98M	250.88M	255.21M
Normalized Net Operating Profit after Tax (NOPAT)	-27	-11	-7.50	-14	-0.48	-9.12	-9.75	1.77	100	102
Normalized NOPAT Margin	-47.31%	-16.17%	-10.21%	-21.89%	-0.65%	-13.64%	-14.15%	2.24%	48.66%	53.54%
Pre Tax Income Margin	-82.44%	-269.39%	-23.06%	-34.92%	885.05%	-30.75%	-19.39%	-5.72%	46.83%	59.48%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.64	-12.40	-1.01	-1.73	43.13	-1.41	-1.87	0.11	10.59	37.28
NOPAT to Interest Expense	-1.85	-8.68	-0.56	-1.22	0.08	-0.93	-1.16	0.15	9.79	32.65
EBIT Less CapEx to Interest Expense	-3.04	-13.03	-1.81	-2.25	42.03	-2.77	-5.44	-0.56	9.98	35.21
NOPAT Less CapEx to Interest Expense	-2.25	-9.31	-1.36	-1.74	-1.01	-2.29	-4.73	-0.52	9.18	30.59
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	-0.19%	-0.18%	-0.35%	-0.82%	-6.94%	68.64%	44.50%	34.64%	30.61%	31.38%
Augmented Payout Ratio	-0.19%	-0.18%	-0.35%	-0.82%	-6.94%	68.64%	44.50%	34.64%	30.61%	31.38%

Frequently Asked Questions About Maravai LifeSciences' Financials

When does Maravai LifeSciences's financial year end?

According to the most recent income statement we have on file, Maravai LifeSciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Maravai LifeSciences' net income changed over the last 2 years?

Maravai LifeSciences' net income appears to be on a downward trend, with a most recent value of -$259.62 million in 2024, falling from $490.66 million in 2022. The previous period was -$138.38 million in 2023. Find out what analysts predict for Maravai LifeSciences in the coming months.

What is Maravai LifeSciences's operating income?

Maravai LifeSciences's total operating income in 2024 was -$235.62 million, based on the following breakdown:

Total Gross Profit: $108.31 million
Total Operating Expenses: $343.93 million

How has Maravai LifeSciences revenue changed over the last 2 years?

Over the last 2 years, Maravai LifeSciences' total revenue changed from $883.00 million in 2022 to $259.19 million in 2024, a change of -70.6%.

How much debt does Maravai LifeSciences have?

Maravai LifeSciences' total liabilities were at $431.04 million at the end of 2024, a 38.2% decrease from 2023, and a 68.7% decrease since 2022.

How much cash does Maravai LifeSciences have?

In the past 2 years, Maravai LifeSciences' cash and equivalents has ranged from $322.40 million in 2024 to $632.14 million in 2022, and is currently $322.40 million as of their latest financial filing in 2024.

How has Maravai LifeSciences' book value per share changed over the last 2 years?

Over the last 2 years, Maravai LifeSciences' book value per share changed from 2.14 in 2022 to 1.29 in 2024, a change of -39.7%.

Related Companies

This page (NASDAQ:MRVI) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maravai LifeSciences (MRVI) Financials

Frequently Asked Questions About Maravai LifeSciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maravai LifeSciences (MRVI) Financials

Annual Income Statements for Maravai LifeSciences

Quarterly Income Statements for Maravai LifeSciences

Annual Cash Flow Statements for Maravai LifeSciences

Quarterly Cash Flow Statements for Maravai LifeSciences

Annual Balance Sheets for Maravai LifeSciences

Quarterly Balance Sheets for Maravai LifeSciences

Annual Metrics And Ratios for Maravai LifeSciences

Quarterly Metrics And Ratios for Maravai LifeSciences

Frequently Asked Questions About Maravai LifeSciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools